stockportfolio.pro
IONS vs PODD: Which Stock Is the Better Buy?
Ionis Pharmaceuticals, Inc. and Insulet Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — IONS vs PODD, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Ionis Pharmaceuticals, Inc. (IONS) | Insulet Corporation (PODD) | |
|---|---|---|
| Market cap | $12.2B | $11.4B |
| Revenue (latest FY) | $943.71M | $2.71B |
| Net income (latest FY) | $-381.39M | $247.10M |
| Revenue growth (5y CAGR) | 5.3% | 24.5% |
| Net margin | -40.4% | 9.1% |
| Return on equity | -78.0% | 16.3% |
| P/E ratio | — | 38.4 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 8 |
| Positive free cash flow | No | Yes |
See the full IONS vs PODD breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open IONS's full financials → Open PODD's full financials →More comparisons
Frequently asked questions
Which is bigger, IONS or PODD?
Ionis Pharmaceuticals, Inc. is larger by market capitalization — $12.2B versus $11.4B.
Which grows faster, IONS or PODD?
Over the last five fiscal years, Insulet Corporation grew revenue faster — 24.5%/yr versus 5.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.